Back to Search
Start Over
Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis
- Source :
- Liver International, Liver International, Wiley-Blackwell, 2020, 40 (8), pp.1853-1859. ⟨10.1111/liv.14502⟩
- Publication Year :
- 2020
- Publisher :
- HAL CCSD, 2020.
-
Abstract
- BACKGROUND Genotype 1b is the most common HCV genotype worldwide, accounting for the largest proportion of infections in Europe, Russia, Latin America and Asia. Reducing treatment duration can improve adherence, reduce drug exposure and cost. Accordingly, we evaluated the efficacy of 8 weeks fixed-dose combination of grazoprevir-elbasvir in treatment-naive patients, with non-severe fibrosis. METHODS HCV mono-infected and treatment naive patients with non-severe fibrosis (Fibroscan®
- Subjects :
- Adult
Cyclopropanes
Male
medicine.medical_specialty
Elbasvir
Asia
Genotype
[SDV]Life Sciences [q-bio]
Fixed-dose combination
Hepacivirus
Antiviral Agents
Gastroenterology
Therapy naive
03 medical and health sciences
0302 clinical medicine
Fibrosis
Quinoxalines
Internal medicine
Ribavirin
medicine
Clinical endpoint
Humans
ComputingMilieux_MISCELLANEOUS
Aged
Benzofurans
Sulfonamides
Hepatology
business.industry
Imidazoles
Middle Aged
medicine.disease
Amides
Hepatitis C
3. Good health
Europe
Grazoprevir
030220 oncology & carcinogenesis
Drug Therapy, Combination
Female
030211 gastroenterology & hepatology
Carbamates
business
Viral load
Subjects
Details
- Language :
- English
- ISSN :
- 14783223 and 14783231
- Database :
- OpenAIRE
- Journal :
- Liver International, Liver International, Wiley-Blackwell, 2020, 40 (8), pp.1853-1859. ⟨10.1111/liv.14502⟩
- Accession number :
- edsair.doi.dedup.....788a274f99cb0b65221011f050bb1e22
- Full Text :
- https://doi.org/10.1111/liv.14502⟩